Significance of Crooke's Hyaline Change in Nontumorous Corticotrophs of Patients With Cushing Disease

被引:8
作者
Akirov, Amit [1 ,2 ,3 ]
Larouche, Vincent [1 ,4 ]
Shimon, Ilan [2 ,3 ]
Asa, Sylvia L. [5 ]
Mete, Ozgur [6 ]
Sawka, Anna M. [7 ,8 ]
Gentili, Fred [9 ,10 ]
Ezzat, Shereen [1 ]
机构
[1] Univ Toronto, Princess Margaret Canc Ctr, Dept Endocrine Oncol, Toronto, ON, Canada
[2] Beilinson Med Ctr, Inst Endocrinol, Petah Tiqwa, Israel
[3] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
[4] McGill Univ, Jewish Gen Hosp, Div Endocrinol & Metab, Montreal, PQ, Canada
[5] Case Western Reserve Univ, Univ Hosp, Dept Pathol, Cleveland, OH 44106 USA
[6] Univ Toronto, Univ Hlth Network, Dept Pathol, Toronto, ON, Canada
[7] Univ Hlth Network, Div Endocrinol, Toronto, ON, Canada
[8] Univ Toronto, Toronto, ON, Canada
[9] Univ Toronto, Univ Hlth Network, Toronto Western Hosp, Div Neurosurg, Toronto, ON, Canada
[10] Univ Toronto, Dept Surg, Toronto, ON, Canada
关键词
Cushing disease; corticotroph tumor; Crooke' s changes; pituitary tumors; pituitary tumor regrowth and recurrence; CORTISOL; SURGERY;
D O I
10.3389/fendo.2021.620005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Glucocorticoid excess in Cushing disease (CD) leads to negative feedback suppression, resulting in Crooke's hyaline change (CC) of nontumorous pituitary corticotrophs. We aimed to determine the predictive value of CC of nontumorous corticotrophs in CD. Methods The retrospective chart review study included patients with clinical, biochemical, radiologic and outcome data and evaluable histopathology specimens from pituitary surgery for CD. The main outcome was remission of CD, defined by clinical features, biochemical testing, and corticosteroid dependency. Results Of 144 CD patients, 60 (50 women, mean age 43.6 +/- 14) had clinical follow-up, biochemical data and histopathology specimens that included evaluable nontumorous adenohypophysis. Specimens from 50 patients (83.3%) demonstrated CC in nontumorous corticotrophs, and 10 (16.7%) had no CC (including 3 with corticotroph hyperplasia). One patient with CC was lost to follow-up and one without CC had equivocal outcome results. During a mean (SD) follow-up period of 74.9 months (61.0), recurrent or persistent disease was documented in 18 patients (31.0%), while 40 (69.0%) were in remission. In patients with CC, the remission rate was 73.5% (95% CI, 59.7%-83.7%) (36/49), whereas it was 44.4% (95% CI, 18.9%-73.3%) (4/9) in patients with no CC. The combination of serum cortisol >138 nmol/L within a week of surgery coupled with absence of nontumorous CC greatly improved the prediction of recurrent or persistent disease. Conclusions CC of nontumorous corticotrophs was observed in 83% of patients with CD, and most patients with CC experienced remission. Absence of CC in nontumorous corticotrophs may serve as a predictor of reduced remission in patients with CD.
引用
收藏
页数:8
相关论文
共 28 条
[1]   Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study [J].
Alexandraki, Krystallenia I. ;
Kaltsas, Gregory A. ;
Isidori, Andrea M. ;
Storr, Helen L. ;
Afshar, Farhad ;
Sabin, Ian ;
Akker, Scott A. ;
Chew, Shern L. ;
Drake, William M. ;
Monson, John P. ;
Besser, G. Michael ;
Grossman, Ashley B. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2013, 168 (04) :639-648
[2]  
Asa SL., 2011, TUMORS PITUITARY GLA
[3]   Cytokeratin profiles in pituitary neuroendocrine tumors [J].
Asa, Sylvia L. ;
Mete, Ozgur .
HUMAN PATHOLOGY, 2021, 107 :87-95
[4]   Immunohistochemical Biomarkers in Pituitary Pathology [J].
Asa, Sylvia L. ;
Mete, Ozgur .
ENDOCRINE PATHOLOGY, 2018, 29 (02) :130-136
[5]   Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance [J].
Atkinson, AB ;
Kennedy, A ;
Wiggam, MI ;
McCance, DR ;
Sheridan, B .
CLINICAL ENDOCRINOLOGY, 2005, 63 (05) :549-559
[6]   A Combined Dexamethasone Desmopressin Test as an Early Marker of Postsurgical Recurrence in Cushing's Disease [J].
Castinetti, Frederic ;
Martinie, Monique ;
Morange, Isabelle ;
Dufour, Henry ;
Sturm, Nathalie ;
Passagia, Jean-Guy ;
Conte-Devolx, Bernard ;
Chabre, Olivier ;
Brue, Thierry .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (06) :1897-1903
[7]   Mortality and Morbidity in Cushing's Disease over 50 Years in Stoke-on-Trent, UK: Audit and Meta-Analysis of Literature [J].
Clayton, R. N. ;
Raskauskiene, D. ;
Reulen, R. C. ;
Jones, P. W. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (03) :632-642
[8]   The role of Crooke's changes in recurrence and remission after gamma knife radiosurgery [J].
Cordeiro, Diogo ;
Xu, Zhiyuan ;
Nasser, Mohammed ;
Lopes, Beatriz ;
Vance, Mary Lee ;
Sheehan, Jason .
JOURNAL OF NEURO-ONCOLOGY, 2019, 142 (01) :171-181
[9]   Evaluation of Cushing's disease remission after transsphenoidal surgery based on early serum cortisol dynamics [J].
Costenaro, Fabiola ;
Rodrigues, Ticiana C. ;
Rollin, Guilherme A. F. ;
Ferreira, Nelson P. ;
Czepielewski, Mauro A. .
CLINICAL ENDOCRINOLOGY, 2014, 80 (03) :411-418
[10]   Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma [J].
Dekkers, O. M. ;
Biermasz, N. R. ;
Pereira, A. M. ;
Roelfsema, F. ;
van Aken, M. O. ;
Voormolen, J. H. C. ;
Romijn, J. A. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (03) :976-981